Cognition Therapeutics Future Growth
Future criteria checks 0/6
Cognition Therapeutics's earnings are forecast to decline at 32.3% per annum while its annual revenue is expected to grow at 46.5% per year. EPS is expected to decline by 15.4% per annum.
Key information
-32.3%
Earnings growth rate
-15.4%
EPS growth rate
| Pharmaceuticals earnings growth | 21.7% |
| Revenue growth rate | 46.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Apr 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30
Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
Aug 15Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
Mar 17Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Sep 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Aug 12Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
Aug 05We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Mar 19Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -92 | -99 | N/A | 3 |
| 12/31/2025 | N/A | -64 | -68 | N/A | 4 |
| 12/31/2024 | N/A | -39 | -56 | -17 | 4 |
| 12/31/2023 | N/A | -26 | -16 | -16 | N/A |
| 9/30/2023 | N/A | -23 | -21 | -21 | N/A |
| 6/30/2023 | N/A | -23 | -17 | -17 | N/A |
| 3/31/2023 | N/A | -24 | -18 | -18 | N/A |
| 12/31/2022 | N/A | -21 | -19 | -19 | N/A |
| 9/30/2022 | N/A | -24 | -8 | -8 | N/A |
| 6/30/2022 | N/A | -22 | -10 | -10 | N/A |
| 3/31/2022 | N/A | -19 | -6 | -6 | N/A |
| 12/31/2021 | N/A | -16 | -4 | -4 | N/A |
| 9/30/2021 | N/A | -12 | -4 | -4 | N/A |
| 6/30/2021 | N/A | -10 | -3 | -3 | N/A |
| 3/31/2021 | N/A | -9 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -12 | -3 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CGTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CGTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CGTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CGTX is forecast to have no revenue next year.
High Growth Revenue: CGTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CGTX's Return on Equity is forecast to be high in 3 years time